Investigating the efficacy and safety of platelet rich plasma in treating hair loss of patients with lichen planopilaris

Investigating the efficacy and safety of platelet rich plasma and topical clobetasol in treating hair loss of patients with lichen planopilaris in comparison to the patients who only use topical clobetasol

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221018056229N1

Enrollment

Registered

2023-01-28

Start date

2022-12-05

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scalp hair lichen planopilaris. Other lichen planus

Interventions

Intervention 1: Intervention group: the patients will receive Behvazan topical clobetasol 0.05% lotion 20 drops every night, and they will also receive 3 courses of PRP in 1-month intervals. Each PRP

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age: 18 years old and more Definite and resistant hair loss due to LPP The patient gives informed consent The patient can participate in regular follow up meetings The patient does not have serious internal disease The patient does not have cutaneous disease in the site of treatment

Exclusion criteria

Exclusion criteria: History of any remedies taken in last month Positive history of liver, kidney, pulmonary, cardiac, and intestinal disease and malignancies Taking any medications for any disease which makes drug reactions possible Accompanying of LPP with generalized lichen planus or erosive mucosal form Other forms of noncicatricial or other forms of cicatricial alopecia except LPP

Design outcomes

Primary

Measure	Time frame
The amount of scalp pruritus based on LPPI. Timepoint: Investigating of scalp hair situation with using dermatoscope, at the first visit, at 1 month and 2 months and then 6 months after the first visit. Method of measurement: Dermatoscopy with dermatoscope.;The amount of scalp erythema based on LPPI. Timepoint: Investigating of scalp hair situation with using dermatoscope, at the first visit, at 1 month and 2 months and then 6 months after the first visit. Method of measurement: Dermatoscopy with dermatoscope.;The amount of scalp scaling based on LPPI. Timepoint: Investigating of scalp hair situation with using dermatoscope, at the first visit, at 1 month and 2 months and then 6 months after the first visit. Method of measurement: Dermatoscopy with dermatoscope.	—

Measure

Time frame

The amount of scalp pruritus based on LPPI. Timepoint: Investigating of scalp hair situation with using dermatoscope, at the first visit, at 1 month and 2 months and then 6 months after the first visit. Method of measurement: Dermatoscopy with dermatoscope.;The amount of scalp erythema based on LPPI. Timepoint: Investigating of scalp hair situation with using dermatoscope, at the first visit, at 1 month and 2 months and then 6 months after the first visit. Method of measurement: Dermatoscopy with dermatoscope.;The amount of scalp scaling based on LPPI. Timepoint: Investigating of scalp hair situation with using dermatoscope, at the first visit, at 1 month and 2 months and then 6 months after the first visit. Method of measurement: Dermatoscopy with dermatoscope.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Lotfi

Iran University of Medical Sciences

zahra_lotfi90@yahoo.com+98 21 6651 4001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026